In summary, our data show that genomic gains of MCL-1 during lung cancer evolution represent a frequent and functionally important survival mechanism for pulmonary adenocarcinoma that represents a rational drug target for the treatment of NSCLC. This evidence concerns the gene MCL1 and lung cancer.